Emery-Dreifuss Muscular Dystrophy Clinical Presentation

  • Author: Glenn Lopate, MD; Chief Editor: Amy Kao, MD   more...
 
Updated: Jun 23, 2011
 

History

History and physical findings of Emery-Dreifuss muscular dystrophy are discussed in this section.

  • The following triad of symptoms strongly suggests EDMD:
    • Slowly progressive muscle weakness and wasting in a scapulohumeroperoneal distribution
    • Early contractures of the elbow, ankle, and posterior neck
    • Cardiac conduction defects, cardiomyopathy, or both
  • Onset is usually in the teenage years, but the condition can present with neonatal hypotonia or through the third decade. Patients typically develop weakness of peroneal muscles with toe-walking late in the first decade or in the early teenage years.
  • Prominent interfamilial and intrafamilial variability can exist, even with the same mutation types. However, sometimes a clear difference between mutation types cannot be found in families.
  • Contractures often present before weakness and may be more disabling.
    • Elbow (unusual except in EDMD)
    • Spine
      • Posterior neck (unusual except in EDMD)
      • Low back (rigid spine)
    • Ankle
  • Weakness
    • Symmetric weakness of the biceps, triceps, and peroneal muscles
    • Scapular winging
    • Face, thigh, and hand weakness (uncommon but may occur late)
    • A limb girdle phenotype can be seen with mutations in EMD, but is more commonly due to a mutation in LMNA.[2]
  • Cardiac disease (nearly universal)
    • Cardiac disease usually begins after onset of weakness and manifests as syncope in the second or third decade.
    • Pacemakers are often needed by age 30 years.
    • Cardiac disease may present with sudden cardiac death.
    • Bradycardia, atrial arrhythmias (including atrial fibrillation/flutter), AV conduction defect, and atrial paralysis have all been reported.
    • Late findings may include atrial or ventricular cardiomyopathy.
    • Of female carriers, 10-20% have atrial arrhythmias or conduction defects and need to be monitored with yearly ECG to try to prevent sudden cardiac death.
    • Conduction defects with minimal muscle and joint involvement may occur.[2]
  • In general, autosomal dominant EDMD is clinically indistinguishable from the X-linked form. A few differences have been noted to be more common in EMD2 and include the following:
    • Muscle weakness is often the initial symptom, before contractures develop.
    • Calf hypertrophy may mimic other forms of childhood muscular dystrophy.
    • Scapular winging is more common.
    • Loss of ambulation is more likely.
    • Isolated or more severe cardiac conduction defects or cardiomyopathy are more common.
Next

Causes

  • X-linked recessive EDMD is caused by a mutation on the X chromosome in the gene encoding emerin (EMD).
    • More than 70 unique mutations throughout the coding and promoter regions have been identified that are most often point mutations, small deletions, or insertions that usually result in stop codons.
    • Emerin protein is usually absent, but, in a few cases, the protein is present but in a reduced amount.
    • Emerin is a 34-kd protein that belongs to a family of nuclear proteins that bind a variety DNA regulatory molecules and to molecules thought to be important in maintaining nuclear membrane structure.
    • Emerin is not essential to cell survival and several animal models that have an emerin knock-out have no overt myopathic phenotype.
  • Autosomal dominant EDMD is caused by a mutation on chromosome 1 in the gene that codes for lamin A/C (LMNA). Sporadic cases are common in large series describing patients with LMNA mutations.
    • Most mutations are missense, nonsense, inframe deletions, or at a splice site.
    • Several diseases are caused by mutations in the LMNA gene; these are termed laminopathies.
      • EMD2
      • Limb-girdle muscular dystrophy with cardiac conduction disturbances (LGMD1B)
      • Dilated cardiomyopathy with conduction system disease (CMD1A)
      • Autosomal recessive axonal neuropathy (CMT2B1)
      • Familial partial lipodystrophy (FPLD)
      • Mandibuloacral dysplasia (MAD)
      • Restrictive dermopathy
      • Progeria syndromes - Hutchinson-Gilford progeria, Werner syndrome (atypical)
    • Interestingly, the same mutation can result in different EDMD phenotypes between individuals and even between siblings with both mild and severely affected patients reported within the same family. Furthermore, the same mutation can also cause different laminopathy syndromes even within the same family. For example, one patient was described with both EDMD and progeria. Another family had EDMD and neuropathy in one member and just neuropathy in another member. In another family, some patients had EDMD, others had LGMD, and still others had dilated cardiomyopathy. The mutation R644C has extreme phenotypic diversity and low penetrance. All of the above syndromes (except restrictive dermopathy) have been reported, at least in part, to be caused by this mutation.[3]
    • No clear correlation exists between clinical phenotype and the site of the mutation, although a few points are worth noting. The most common mutation in EMD2 is at R453W and accounts for about 15% of cases. The most common mutation in FPLD is at R482W/Q/L and accounts for about 85% of cases.
    • The lamin A/C tail region between amino acids 430 and 545 adopts an immunoglobulinlike fold, which is likely important in the interaction of lamin A/C with other proteins (or DNA). Many mutations that cause muscle disease (EMD, LGMD1B) affect buried residues at the core of the immunoglobulin structure, which are believed to play a role in the integrity of the immunoglobulinlike fold and may destabilize the carboxyl-terminus tail of lamin A/C, resulting in a loss of structurally functional lamin A/C. Other mutations throughout lamin A/C in muscle disease also suggest a change in protein structure. Mutations in the immunoglobulinlike domain that cause FPLD affect only solvent-accessible amino acids that lead to a decrease in positive surface charge.
  • EMD3 is caused by a mutation on chromosome 6 in synaptic nuclear envelope protein 1 (SYNE1; Nesprin-1 α) and EMD4 is caused by a mutation in synaptic nuclear envelope protein 2 (SYNE2; Nesprin-2 β).[1]
    • Nesprins are spectrin-repeat proteins that are present in many subcellular locations, including the nucleus, the inner and outer nuclear membranes, in association with mitochondria and the Golgi apparatus, throughout the sarcomere, and at the plasma membrane. The nesprins form a network linking these structures to the actin cytoskeleton.
    • By binding to lamins and emerin, nesprins link the nucleoskeleton and inner nuclear membrane to the outer nuclear membrane and cytoskeleton. Disruption of this interaction may be responsible for the complex phenotypes associated with EDMD.
Previous
 
 
Contributor Information and Disclosures
Author

Glenn Lopate, MD  Associate Professor, Department of Neurology, Division of Neuromuscular Diseases, Washington University School of Medicine; Director of Neurology Clinic, St Louis ConnectCare; Consulting Staff, Department of Neurology, Barnes-Jewish Hospital

Glenn Lopate, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and Phi Beta Kappa

Disclosure: Baxter Grant/research funds Other; Amgen Grant/research funds None

Specialty Editor Board

James J Riviello Jr, MD  George Peterkin Endowed Chair in Pediatrics, Professor of Pediatrics, Section of Neurology and Developmental Neuroscience, Professor of Neurology, Peter Kellaway Section of Neurophysiology, Baylor College of Medicine; Chief of Neurophysiology, Director of the Epilepsy and Neurophysiology Program, Texas Children's Hospital

James J Riviello Jr, MD is a member of the following medical societies: American Academy of Pediatrics

Disclosure: Up To Date Royalty Section Editor

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Kenneth J Mack, MD, PhD  Senior Associate Consultant, Department of Child and Adolescent Neurology, Mayo Clinic

Kenneth J Mack, MD, PhD is a member of the following medical societies: American Academy of Neurology, Child Neurology Society, Phi Beta Kappa, and Society for Neuroscience

Disclosure: Nothing to disclose.

Chief Editor

Amy Kao, MD  Attending Neurologist, Children's National Medical Center

Amy Kao, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Pediatrics, American Epilepsy Society, and Child Neurology Society

Disclosure: Nothing to disclose.

References
  1. Zhang Q, Bethmann C, Worth NF, et al. Nesprin-1 and -2 are involved in the pathogenesis of Emery-Dreifuss muscular dystrophy and are critical for nuclear envelope integrity. Hum Mol Genet. Dec 2007;16:2816-2833. [Medline].

  2. Astejada MN, Goto K, Nagano A, et al. Emerinopathy and laminopathy clinical, pathological and molecular features of muscular dystrophy with nuclear envelopathy in Japan. Acta Myol. Dec 2007;26:159-164. [Medline].

  3. Rankin J, Auer-Grumbach M, Bagg W, et al. Extreme phenotypic diversity and nonpenetrance in families with the LMNA gene mutation R644C. Am J Med Genet. Jun 2008;146A:1530-1542. [Medline].

  4. Fidzianska A, Glinka Z. Nuclear architecture remodelling in envelopathies. Folia Neuropathol. 2007;45:47-55. [Medline].

  5. Benedetti S, Bertini E, Iannaccone S, et al. Dominant LMNA mutations can cause combined muscular dystrophy and peripheral neuropathy. J Neurol Neurosurg Psychiatry. 2005;76:1019-21. [Medline].

  6. Bengtsson L, Wilson KL. Multiple and surprising new functions for emerin, a nuclear membrane protein. Curr Opin Cell Biol. Feb 2004;16(1):73-9. [Medline].

  7. Bione S, Maestrini E, Rivella S, et al. Identification of a novel X-linked gene responsible for Emery-Dreifuss muscular dystrophy. Nat Genet. Dec 1994;8(4):323-7. [Medline].

  8. Bonne G, Di Barletta MR, Varnous S, et al. Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat Genet. Mar 1999;21(3):285-8. [Medline].

  9. Bonne G, Yaou RB, Béroud C, et al. 108th ENMC International Workshop, 3rd Workshop of the MYO-CLUSTER project: EUROMEN, 7th International Emery-Dreifuss Muscular Dystrophy (EDMD) Workshop, 13-15 September 2002, Naarden, The Netherlands. Neuromuscul Disord. Aug 2003;13(6):508-15. [Medline].

  10. Cao H, Hegele RA. Nuclear lamin A/C R482Q mutation in canadian kindreds with Dunnigan-type familial partial lipodystrophy. Hum Mol Genet. Jan 1 2000;9(1):109-12. [Medline].

  11. Cartegni L, di Barletta MR, Barresi R, et al. Heart-specific localization of emerin: new insights into Emery-Dreifuss muscular dystrophy. Hum Mol Genet. Dec 1997;6(13):2257-64. [Medline].

  12. Chakrabarti A, Pearce JM. Scapuloperoneal syndrome with cardiomyopathy: report of a family with autosomal dominant inheritance and unusual features. J Neurol Neurosurg Psychiatry. Dec 1981;44(12):1146-52. [Medline].

  13. Dreifuss FE, Hogan GR. Survival in x-chromosomal muscular dystrophy. Neurology. Aug 1961;11:734-7. [Medline].

  14. Ellis JA, Yates JR, Kendrick-Jones J, Brown CA. Changes at P183 of emerin weaken its protein-protein interactions resulting in X-linked Emery-Dreifuss muscular dystrophy. Hum Genet. Mar 1999;104(3):262-8. [Medline].

  15. Emery AE, Dreifuss FE. Unusual type of benign x-linked muscular dystrophy. J Neurol Neurosurg Psychiatry. Aug 1966;29(4):338-42. [Medline].

  16. English KM, Gibbs JL. Cardiac monitoring and treatment for children and adolescents with neuromuscular disorders. Dev Med Child Neurol. Mar 2006;48(3):231-5. [Medline].

  17. Fairley EA, Kendrick-Jones J, Ellis JA. The Emery-Dreifuss muscular dystrophy phenotype arises from aberrant targeting and binding of emerin at the inner nuclear membrane. J Cell Sci. Aug 1999;112 ( Pt 15):2571-82. [Medline].

  18. Fatkin D, MacRae C, Sasaki T, et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med. Dec 2 1999;341(23):1715-24. [Medline].

  19. Gruenbaum Y, Margalit A, Goldman RD, et al. The nuclear lamina comes of age. Nat Rev Mol Cell Biol. Jan 2005;6(1):21-31. [Medline].

  20. Higuchi Y, Hongou M, Ozawa K, et al. A family of Emery-Dreifuss muscular dystrophy with extreme difference in severity. Pediatr Neurol. May 2005;32(5):358-60. [Medline].

  21. Holaska JM, Kowalski AK, Wilson KL. Emerin caps the pointed end of actin filaments: evidence for an actin cortical network at the nuclear inner membrane. PLoS Biol. Sep 2004;2(9):E231. [Medline].

  22. Jacob KN, Garg A. Laminopathies: multisystem dystrophy syndromes. Mol Genet Metab. Apr 2006;87(4):289-302. [Medline].

  23. Kirschner J, Brune T, Wehnert M, et al. p.S143F mutation in lamin A/C: a new phenotype combining myopathy and progeria. Ann Neurol. Jan 2005;57(1):148-51. [Medline].

  24. Liu J, Lee KK, Segura-Totten M, et al. MAN1 and emerin have overlapping function(s) essential for chromosome segregation and cell division in Caenorhabditis elegans. Proc Natl Acad Sci U S A. Apr 15 2003;100(8):4598-603. [Medline].

  25. Manilal S, Sewry CA, Pereboev A, et al. Distribution of emerin and lamins in the heart and implications for Emery-Dreifuss muscular dystrophy. Hum Mol Genet. Feb 1999;8(2):353-9. [Medline].

  26. Mercuri E, Brown SC, Nihoyannopoulos P, et al. Extreme variability of skeletal and cardiac muscle involvement in patients with mutations in exon 11 of the lamin A/C gene. Muscle Nerve. May 2005;31(5):602-9. [Medline].

  27. Miller RG, Layzer RB, Mellenthin MA, et al. Emery-Dreifuss muscular dystrophy with autosomal dominant transmission. Neurology. Aug 1985;35(8):1230-3. [Medline].

  28. Muchir A, Bonne G, van der Kooi AJ, et al. Identification of mutations in the gene encoding lamins A/C in autosomal dominant limb girdle muscular dystrophy with atrioventricular conduction disturbances (LGMD1B). Hum Mol Genet. May 22 2000;9(9):1453-9. [Medline].

  29. Ostlund C, Worman HJ. Nuclear envelope proteins and neuromuscular diseases. Muscle Nerve. Apr 2003;27(4):393-406. [Medline].

  30. Raffaele Di Barletta M, Ricci E, Galluzzi G. Different mutations in the LMNA gene cause autosomal dominant and autosomal recessive Emery-Dreifuss muscular dystrophy. Amer J Human Genet. 2000;66:1407-12. [Medline].

  31. van Berlo JH, de Voogt WG, van der Kooi AJ, et al. Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death?. J Mol Med. Jan 2005;83(1):79-83. [Medline].

  32. van der Kooi AJ, Bonne G, Eymard B, et al. Lamin A/C mutations with lipodystrophy, cardiac abnormalities, and muscular dystrophy. Neurology. Aug 27 2002;59(4):620-3. [Medline].

  33. Zastrow MS, Vlcek S, Wilson KL. Proteins that bind A-type lamins: integrating isolated clues. J Cell Sci. Mar 1 2004;117(Pt 7):979-87. [Medline].

Previous
Next
 
Left: The photomicrograph is a muscle biopsy with normal emerin immunostaining. Right: The micrograph is from a patient with X-linked Emery-Dreifuss muscular dystrophy. Note the absence of nuclear staining as well as the hypertrophied and atrophied muscle fibers.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.